NYSE:FNA - New York Stock Exchange, Inc. - US69913P1057 - Common Stock - Currency: USD
PARAGON 28 INC
NYSE:FNA (2/4/2025, 8:04:01 PM)
After market: 13 0 (0%)13
-0.01 (-0.08%)
The current stock price of FNA is 13 USD. In the past month the price increased by 18.94%. In the past year, price decreased by -10.1%.
Let's have a look at the stocks with an unusual volume in today's session.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.64 | 223.92B | ||
ISRG | INTUITIVE SURGICAL INC | 79.08 | 206.46B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.87 | 152.60B | ||
SYK | STRYKER CORP | 32.19 | 149.59B | ||
MDT | MEDTRONIC PLC | 17.33 | 116.65B | ||
BDX | BECTON DICKINSON AND CO | 18.42 | 70.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.72 | 42.07B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.6 | 39.72B | ||
IDXX | IDEXX LABORATORIES INC | 41.34 | 38.08B | ||
RMD | RESMED INC | 27.2 | 35.30B | ||
DXCM | DEXCOM INC | 51.45 | 34.16B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.23 | 25.29B |
Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado and currently employs 430 full-time employees. The company went IPO on 2021-10-21. The firm provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. The company has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.
PARAGON 28 INC
14445 Grasslands Drive
Englewood COLORADO US
Employees: 574
Company Website: https://paragon28.com/
Investor Relations: https://ir.paragon28.com/
Phone: 17209121332
The current stock price of FNA is 13 USD.
The exchange symbol of PARAGON 28 INC is FNA and it is listed on the New York Stock Exchange, Inc. exchange.
FNA stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for FNA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of FNA.
FNA does not pay a dividend.
FNA will report earnings on 2025-02-27, after the market close.
FNA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
The outstanding short interest for FNA is 7.48% of its float.
ChartMill assigns a technical rating of 9 / 10 to FNA. When comparing the yearly performance of all stocks, FNA is one of the better performing stocks in the market, outperforming 90.55% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to FNA. The financial health of FNA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months FNA reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by -48.98% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.89% | ||
ROE | -45.24% | ||
Debt/Equity | 0.79 |
ChartMill assigns a Buy % Consensus number of 85% to FNA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -13.97% and a revenue growth 17.57% for FNA